Release Date: November 26, 2025
Expiration Date: November 26, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in dry eye disease (DED). In this educational program, these experts use a case-based format to discuss the latest data regarding the management of DED and share their perspectives and best practices.
This educational activity is an archive of the live virtual symposium held on October 10, 2025.
Target Audience
This educational activity is directed toward optometrists and other eye care professionals involved in the management of patients with dry eye disease.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the neural network that monitors the ocular surface environment and regulates tear secretion
- Assess the mechanisms of action of neuromodulation therapeutics in dry eye disease (DED)
- Evaluate current and emerging therapeutics for DED
- Identify clinical applications and patient selection for neuromodulation therapies in DED
Janelle L. Davison, OD
Owner and Clinical Director
Brilliant Eyes Vision Center
Visionary Dry Eye Institute
Smyrna, GA
Disclosures: Janelle L. Davison, OD, has no relevant financial relationships with ineligible companies.
Cecelia Koetting, OD, FAAO, DipABO
Assistant Professor
Department of Ophthalmology
University of Colorado
Anschutz School of Medicine
Denver, CO
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie/Allergan, Alcon Inc, Bausch + Lomb, Dompé, Harrow, Movu, Myze, Orasis Pharmaceuticals, Tarsus Pharmaceuticals, Topcon, Viatris Inc, Visus; Grant/Research Funding: Kala Bio
Cory J. Lappin, OD, MS, FAAO
Founder
The Dry Eye Center of Ohio
Cincinnati, OH
Disclosures: Advisory Board, Consultant, Speaker: Alcon, Barti, Bausch + Lomb, Bruder Healthcare and M&S Technologies (Hilco Vision), CSI Dry Eye Software, Dompé Pharmaceuticals, Eyederm, Eyenovia, Harrow, Lumenis, Myze, Nordic Pharma, Norwood Device & Diagnostics, NuLids, Ocubio, PRN Vision Group, Rinsada, SCOPE Health, Sight Sciences, Tarsus Pharmaceuticals, TearRestore, Viatris Inc (Oyster Point Pharma), Vital Tears LLC; Investment: Barti, Myze, NuLids; Ownership Stake: Eyederm; Executive Team Member: Myze; Medical Director: Norwood Device & Diagnostics
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here